Table 1 Probability, cost and utility used in decision analysis models for metformin versus insulin therapy for GDM

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Parameter | Probabilities | Utilities | Costs | Reference |
| Success of metformin treatment | 0.76 | 1 | ¥11234.01 | [12] [13] |
| Failure of metformin treatment | 0.24 | 0.65 | ¥11234.01 | [12] [13, 16] |
| Success of insulin treatment | 0.71 | 1 | ¥11937.81 | [12] [13] [14] |
| Failure of insulin treatment | 0.29 | 0.65 | ¥11937.81 | [12] [13] [14, 16] |

Table 2 Incremental cost-effectiveness analysis

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Groups | C(¥) | △C(¥) | U(QALYs) | △E(QALYs) | ICUR |
| Metformin group | 11234.01 | 0 | 0.26564 | 0 |  |
| Insulin group | 11938.77 | 704.76 | 0.26056 | -0.00507 | -138868.96522 |

Table 3 Range of parameter variations for univariate sensitivity analyses

|  |  |  |  |
| --- | --- | --- | --- |
| Parameters | Base line | Parameter variation range | |
| lower limit | upper limit |
| Cost of metformin treatment（C1） | 428.19 | 321.1425 | 535.2375 |
| Cost of insulin treatment（C2） | 1132.95 | 849.7125 | 1416.1875 |
| Hospitalization expenses（C3） | 10805.82 | 8104.365 | 13507.275 |
| Probability of success in metformin therapy（P1） | 0.76 | 0.684 | 0.836 |
| Probability of failure in metformin therapy（P3） | 0.24 | 0.216 | 0.264 |
| Probability of success in insulin therapy（P2） | 0.71 | 0.639 | 0.781 |
| Probability of failure in insulin therapy（P4） | 0.29 | 0.261 | 0.319 |
| Treatment success utility value（U1） | 1 | 0.9 | 1.1 |
| Treatment failure utility value（U2） | 0.65 | 0.585 | 0.715 |